Radiofrequency ablation (RFA) vs. argon plasma coagulation (APC) for the management of gastric antral vascular ectasia (GAVE) in patients with and without cirrhosis: results from a retrospective analysis of a large cohort of patients treated at a single center

 

 Buy Article Permissions and Reprints

Abstract

Introduction and study aims Gastric antral vascular ectasia (GAVE) is a mucosal abnormality associated with multiple conditions, most notably cirrhosis and systemic sclerosis, that causes indolent gastrointestinal bleeding. It is primarily managed with endoscopic therapy. Traditionally, GAVE is endoscopically ablated using argon plasma coagulation (APC) but radiofrequency ablation (RFA) is emerging as an alternative modality. No prior comparison of the 2 modalities has been published.

We retrospectively compared the effects of GAVE ablation with either RFA, APC or both in the largest cohort of patients thus far presented. We also attempt to discern what effect concomitant cirrhosis has on response to treatment.

Patients and methods After receiving IRB approval, we reviewed our electronic health records to identify all patients who underwent endoscopic evaluation for GAVE between January, 2011 and October, 2016. We compared important variables between APC and RFA, as well as between cirrhosis and non-cirrhosis, using the Chi-square test and the Wilcoxon two-sample test as appropriate.

Results During our study period, 81 patients were endoscopically evaluated for GAVE. 24 patients were treated with APC alone, 28 with RFA alone and 25 patients received both treatment modalities.

APC-treated patients underwent a mean of 2.4 treatment sessions with a mean of 205 days between treatments. RFA-treated patients underwent a mean of 2.3 treatment sessions with a mean of 100 days between treatments.

Hemoglobin values remained stable or increased in all patients during our study period and there were no significant differences in Hgb trend between those treated with APC and those with RFA.

Conclusions RFA and APC were both effective in treating bleeding from GAVE. Though we found subtle differences, patients underwent a similar number of treatment sessions and had similar procedure times and a similar time between sessions no matter the treatment modality used.

• References

• 1 Fuccio L, Mussetto A, Laterza L. et al. Diagnosis and management of gastric antral vascular ectasia. World J Gastrointestinal Endosc 2013; 5: 6-13
  PubMedGoogle Scholar
• 2 Yusoff I, Brennan F, Ormonde D. et al. Argon plasma coagulation for treatment of watermelon stomach. Endoscopy 2002; 34: 407-410
  Article in Thieme ConnectPubMedGoogle Scholar
• 3 Roman S, Saurin JC, Dumortier J. et al. Tolerance and efficacy of argon plasma coagulation for controlling bleeding in patients with typical and atypical manifestations of watermelon stomach. Endoscopy 2003; 35: 1024-1028
  Article in Thieme ConnectPubMedGoogle Scholar
• 4 Boltin D, Gingold-Belfer R, Lichtenstein L. et al. Long-term treatment outcome of patients with gastric vascular ectasia treated with argon plasma coagulation. Europ J Gastroenterol Hepato 2014; 26: 588-593
  PubMedGoogle Scholar
• 5 Sato T, Yamazaki K, Akaike J. Endoscopic band ligation versus argon plasma coagulation for gastric antral vascular ectasia associated with liver diseases. Dig Endosc 2012; 24: 237-242
  CrossrefPubMedGoogle Scholar
• 6 Ward EM, Raimondo M, Rosser BG. et al. Prevalence and natural history of gastric antral vascular ectasia in patients undergoing orthotopic liver transplantation. J Clin Gastroenterol 2004; 38: 898-900
  CrossrefPubMedGoogle Scholar
• 7 Yamada M, Ichikawa M, Takahara O. et al. Gastroduodenal vascular ectasia in patients with liver cirrhosis. Dig Endosc 1999; 11: 241-245
  CrossrefPubMedGoogle Scholar
• 8 Spahr L, Villeneuve JP, Dufresne MP. et al. Gastric antral vascular ectasia in cirrhotic patients: absence of relation with portal hypertension. Gut 1999; 44: 739-742
  CrossrefPubMedGoogle Scholar
• 9 Gostout CJ, Viggiano TR, Ahlquist DA. et al. The clinical and endoscopic spectrum of the watermelon stomach. J Clin Gastroenterol 1992; 15: 256-263
  CrossrefPubMedGoogle Scholar
• 10 Selinger CP, Ang YS. Gastric antral vascular ectasia (GAVE): an update on clinical presentation, pathophysiology and treatment. Digestion 2008; 77: 131-137
  CrossrefPubMedGoogle Scholar
• 11 El-Gendy H, Shohdy KS, Maghraby GG. et al. Gastric antral vascular ectasia in systemic sclerosis: Where do we stand?. Int J Rheum Dis 2017; DOI: 10.111/1756-185X.13047.
  CrossrefPubMedGoogle Scholar
• 12 Swanson E, Mahgoub A, MacDonald R. et al. Medical and endoscopic therapies for angiodysplasia and gastric antral vascular ectasia: a systematic review. Clin Gastroenterol Hepatol 2014; 12: 571-582
  CrossrefPubMedGoogle Scholar
• 13 Dray X, Repici A, Gonzalez P. et al. Radiofrequency ablation for the treatment of gastric antral vascular ectasia. Endoscopy 2014; 46: 963-969
  Article in Thieme ConnectPubMedGoogle Scholar
• 14 McGorisk T, Krishnan K, Keefer L. et al. Radiofrequency ablation for refractory gastric antral vascular ectasia (with video). Gastrointest Endosc 2013; 78: 584-588
  CrossrefPubMedGoogle Scholar
• 15 Raza N, Diehl DL. Radiofrequency ablation of treatment-refractory gastric antral vascular ectasia (GAVE). Surg Laparosc Endosc Percuta Tech 2015; 25: 79-82
  PubMedGoogle Scholar
• 16 Jana T, Thosani N, Fallon MB. et al. Radiofrequency ablation for treatment of refractory gastric antral vascular ectasia (with video). Endoscopy Intern Open 2015; 3: E125-E127
  PubMedGoogle Scholar
• 17 Gross SA, Al-Haddad M, Gill KR. et al. Endoscopic mucosal ablation for the treatment of gastric antral vascular ectasia with the HALO90 system: a pilot study. Gastrointest Endosc 2008; 67: 324-327
  CrossrefPubMedGoogle Scholar